| Kylie Theis, PT | |
|
1725 Western Ave Ste B, Findlay, OH 45840-1390 | |
| (419) 422-5526 | |
| Not Available |
| Full Name | Kylie Theis |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 7 Years |
| Location | 1725 Western Ave Ste B, Findlay, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285159558 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (Ohio) | Secondary |
| 225100000X | Physical Therapist | PT017151 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Opti-health Group Inc | 2264417716 | 10 |
News Archive
Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday).
Drug manufacturers have been adjusting to strict new government standards that limit the amount of potentially harmful impurities in medicine, according to the cover story of the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine. The impurities are "genotoxic," capable of damaging the DNA in genes.
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Manhattan Scientifics, Inc. (OTCBB: MHTX) announced the signing of a contract with Carpenter Technology Corporation (NYSE: CRS), wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. The contract includes minimum annual payments to Manhattan Scientifics during a 4-year period, together with royalty payments as a percent of gross sales.
› Verified 3 days ago
| Provider Name | The Opti-health Group Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356322259 PECOS PAC ID: 2264417716 Enrollment ID: O20040621000480 |
News Archive
Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday).
Drug manufacturers have been adjusting to strict new government standards that limit the amount of potentially harmful impurities in medicine, according to the cover story of the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine. The impurities are "genotoxic," capable of damaging the DNA in genes.
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Manhattan Scientifics, Inc. (OTCBB: MHTX) announced the signing of a contract with Carpenter Technology Corporation (NYSE: CRS), wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. The contract includes minimum annual payments to Manhattan Scientifics during a 4-year period, together with royalty payments as a percent of gross sales.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kylie Theis, PT 1725 Western Ave Ste B, Findlay, OH 45840-1390 Ph: () - | Kylie Theis, PT 1725 Western Ave Ste B, Findlay, OH 45840-1390 Ph: (419) 422-5526 |
News Archive
Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday).
Drug manufacturers have been adjusting to strict new government standards that limit the amount of potentially harmful impurities in medicine, according to the cover story of the current issue of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine. The impurities are "genotoxic," capable of damaging the DNA in genes.
The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.
Manhattan Scientifics, Inc. (OTCBB: MHTX) announced the signing of a contract with Carpenter Technology Corporation (NYSE: CRS), wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. The contract includes minimum annual payments to Manhattan Scientifics during a 4-year period, together with royalty payments as a percent of gross sales.
› Verified 3 days ago
Boyd Davis Iii, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 724 Winterberry Dr, Findlay, OH 45840 Phone: 520-419-9808 | |
Michael J Zimmerman, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1501 Bright Rd, Findlay, OH 45840 Phone: 419-425-6786 Fax: 419-425-8570 | |
Rachel Liza Diller, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 7595 County Road 236, Findlay, OH 45840 Phone: 419-427-1984 | |
Matthew Recker, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 7595 County Road 236, Findlay, OH 45840 Phone: 419-427-1984 Fax: 419-427-2864 | |
Mrs. Stephanie M Cone, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7595 County Road 236, Findlay, OH 45840 Phone: 419-427-1984 | |
Kim Gerken, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 7595 County Road 236, Findlay, OH 45840 Phone: 419-427-1984 Fax: 419-427-2326 | |
Mrs. Heidi M Jolliff, MPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1725 Western Ave, Suite B, Findlay, OH 45840 Phone: 419-422-5526 Fax: 419-422-5562 |